Novavax (NVAX) EBIT (2010 - 2026)

Novavax's EBIT history runs 17 years deep, the most recent figure standing at -$15.4 million for Q1 2026.

• In Q1 2026, EBIT fell 102.99% year-over-year to -$15.4 million; the TTM figure through Mar 2026 stood at -$78.1 million (down 119.0% YoY), while the FY2025 annual figure was $452.8 million, up 281.9% from the prior year.
• EBIT was -$15.4 million for Q1 2026 at Novavax, down from $14.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $515.5 million in Q1 2025 to a low of -$483.0 million in Q2 2022.
• Historically, EBIT has averaged -$60.2 million across 5 years, with a median of -$127.2 million in 2022.
• The sharpest annual moves came in 2023 and 2025: EBIT tumbled 249.44% in 2023, then soared 455.94% in 2025.
• A 5-year view of EBIT shows it stood at -$243.9 million in 2022, then grew by 24.73% to -$183.6 million in 2023, then increased by 28.59% to -$131.1 million in 2024, then jumped by 110.86% to $14.2 million in 2025, then sank by 208.43% to -$15.4 million in 2026.
• The last three EBIT figures came in at -$15.4 million (Q1 2026), $14.2 million (Q4 2025), and -$178.0 million (Q3 2025), per Business Quant data.